The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 13
- 试验地点
- 2
- 主要终点
- Plasma insulin levels
研究概览
简要总结
Our hypothesis is that TA-65, a dietary supplement will help to reduce insulin resistance and plasma glucose in individuals classified with metabolic syndrome.
详细描述
This is double blind cross over randomized clinical trial. The supplement and placebo will be provided by TA Science, Inc. and prepared as described below. Subjects will be randomly allocated to consume either a daily serving of TA-65 (two capsules per day of 8 mg each) (please see attached label) or a placebo for 12 weeks. Randomization will be done in a sequential manner; the first subject will be allocated to supplement A and the next one to supplement B and so on. After a 3-week washout, they will be allocated to the alternate treatment for additional 12 weeks. Supplements (TA-65 or placebo) will be taken twice daily with a meal.
Participants will be advised not to change their diet or exercise protocols during the 27 week intervention. Volunteers will be required to provide a 5-day dietary record before starting the study, at the end of each supplement period (TA-65 or placebo) and at the end of the washout period. Subjects will have to fill an exercise questionnaire during the same times to ensure that there are no changes in physical activity. Participants will be asked to report to the department every 4 weeks for checking compliance on supplement intake and to assess weight and blood pressure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 35 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The inclusion criteria are:
- •men and women (40-70 y) with metabolic syndrome which means having at least 3 of the following characteristics:
- •Blood pressure > 130/85 mm Hg
- •plasma glucose > 100 mg/dL
- •plasma triglycerides > 150 mg/dL
- •HDL cholesterol < 40 mg/dL (men) and < 50 mg/dL (women)
- •waist circumference >102 cm (men) and ≥ 88 cm (women)
- •Women of childbearing age should be using contraception
排除标准
- •Exclusion criteria will be
- •self-reported diabetes mellitus
- •coronary heart disease
- •triglycerides greater than 400 mg/dL
- •Fasting glucose greater than 126 mg/dL
- •Blood pressure greater than 140/100 mmg Hg
- •history of stroke
- •Use of alcohol at an elevated rate (more than two drinks per day)
- •Renal problems
- •liver disease
- •pregnancy and lactation
- •severe infectious diseases
- •autoimmune disease currently under treatment
- •current hormone therapy
- •previous treatment with TA-
- •Intake of glucose-lowering prescriptions
- •Use of immunosuppressants, lithium or supplements such as Sulphonylureas (Glucotrol, Amaryl), Thiazolidinedione (Avandia, ACTOS,), Meglitinides (Prandin, Starlix), Biguanides (Metformin), Alpha-glucosidase inhibitors (Precose, Glyset), dipeptidyl peptidase (DPP)-4 inhibitors (Januvia, Onglyza)
- •high dose chromium or cinnamon supplements
- •Consistent intake of vitamin, mineral, or multivitamin supplements prior to recruitment may be admitted into the study if they plan on maintaining their current supplement program.
- •However, subjects may not participate if they begin taking a new supplement during the 27-wk study period.
- •Subjects will also be asked to refrain from taking any additional supplements, including fish oil, herb and concentrated antioxidant sources.
结局指标
主要结局
Plasma insulin levels
时间窗: 27 weeks
The supplement is anticipated to decrease insulin resistance in individuals with metabolic syndrome. The investigators will measure plasma insulin and plasma glucose as outcomes measures
次要结局
- plasma HDL cholesterol(27 weeks)